• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Tectonic Therapeutic Inc.

    4/25/25 4:13:17 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECX alert in real time by email
    DEFA14A 1 d949345ddefa14a.htm DEFA14A DEFA14A
     
     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under § 240.14a-12

    TECTONIC THERAPEUTIC, INC.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    TECTONIC THERAPEUTIC, INC. 490 ARSENAL WAY SUITE 210 WATERTOWN, MA 02472 Your Vote Counts! TECTONIC THERAPEUTIC, INC. 2025 Annual Meeting Vote by June 5, 2025 11:59 PM ET V72363-P31559 You invested in TECTONIC THERAPEUTIC, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 6, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 23, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Virtually at: Vote Virtually at the Meeting* June 6, 2025 8:00 AM, EDT www.virtualshareholdermeeting.com/TECX2025 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    1. Election of Directors Nominees: 1a. Alise Reicin, M.D. For 1b. Praveen Tipirneni, M.D. For 2. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3.Advisory approval of the compensation of the Company’s Named Executive Officers. For 4.Advisory vote on the frequency of stockholder advisory votes on executive compensation. 1 Year NOTE: Such other business as may properly come before the meeting or any adjournment thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V72364-P31559

    Get the next $TECX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TECX

    DatePrice TargetRatingAnalyst
    4/21/2025$51.00Outperform
    Mizuho
    11/20/2024$65.00Outperform
    Raymond James
    8/22/2024$55.00Overweight
    Wells Fargo
    6/26/2024Overweight
    Piper Sandler
    6/24/2024Buy
    TD Cowen
    More analyst ratings

    $TECX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tectonic Therapeutic Inc.

      SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      11/14/24 4:05:11 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

      SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      10/28/24 6:08:43 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

      SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      10/24/24 5:12:09 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/11/25 6:12:08 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/9/25 5:38:10 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $39,999,977 worth of shares (789,294 units at $50.68), increasing direct ownership by 3% to 4,226,058 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      2/7/25 4:21:19 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Tectonic Therapeutic with a new price target

      Mizuho initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $51.00

      4/21/25 8:39:06 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Tectonic Therapeutic with a new price target

      Raymond James initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $65.00

      11/20/24 7:46:41 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo initiated coverage on Tectonic Therapeutic with a new price target

      Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $55.00

      8/22/24 7:34:40 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tectonic Therapeutic Inc.

      SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      5/15/25 2:24:51 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tectonic Therapeutic Inc.

      SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      5/12/25 10:43:30 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Tectonic Therapeutic Inc.

      424B3 - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      5/8/25 4:33:19 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TECX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

      Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 daysTX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions ("LVEF"), including LVEF≥50% and LVEF 41-49% WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic") today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in pat

      5/17/25 10:40:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

      Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ("PH-HFpEF")Full results from the Phase 1b Part A trial will be presented on May 17, 2025 at the European Society of Cardiology (ESC) Heart Failure Congress in Belgrade, SerbiaPart B of the TX45 Phase 1b trial initiated in March with topline results expected in the second half of 2025Ongoing TX45 APEX Phase 2 trial continues to enroll with topline results expected in 2026Cash and cash equivalents were $306.2 million as of March 31, 2025, including

      5/8/25 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference

      WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Bank of America Securities 2025 Health Care Conference taking place in Las Vegas on May 12-15, 2025. Bank of America Securities Health Care Conference Date:Thursday, May 15th, 2025Time:9:20am PDTFormat:Corporate PresentationPresenter:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link The

      5/7/25 8:00:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/11/25 6:12:08 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/9/25 5:38:10 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Mcguire Terrance sold $8,550,000 worth of shares (500,000 units at $17.10) (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/7/25 5:02:43 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Financials

    Live finance-specific insights

    See more
    • Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

      TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

      1/30/25 6:30:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

      Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

      11/7/24 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

      TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

      8/14/24 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care